Duquesne Family Office LLC
NEW YORK, NY · CIK 0001536411
Portfolio Value: $2.95B
Positions: 73
Period: 2024-09-30
Filed: 2024-11-14
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020Q2 2020Q1 2020Q4 2019Q3 2019Q2 2019Q1 2019Q4 2018Q3 2018Q2 2018Q1 2018Q4 2017Q3 2017Q2 2017Q1 2017Q4 2016Q3 2016Q2 2016Q1 2016Q4 2015Q3 2015Q2 2015Q1 2015Q4 2014Q3 2014Q2 2014Q1 2014Q4 2013Q3 2013Q2 2013
Portfolio Value
$2.95B
Positions
73
New
19
Increased
24
Decreased
19
Sold Out
476
Duquesne Family Office LLC Q3 2024 13F Filing Summary
Duquesne Family Office LLC (NEW YORK, NY) reported a portfolio value of $2.95B across 73 positions in their Q3 2024 SEC 13F filing (period ending 2024-09-30). Top holdings include NTRA ($452.81M), CPNG ($287.14M), COHR ($264.82M). The top 10 positions account for 65.6% of the portfolio. This quarter saw 19 new positions, 24 increases, 19 reductions, 476 complete exits. Notable new buys: ASND ($39.57M), NVT ($31.69M), CNM ($21.10M). Notable exits: OPCH, MDEX, NWSA.
All Holdings
Showing 1-50 of 73
Position Changes
| Stock | Value | Shares |
|---|---|---|
ASNDAscendis Pharma A/S | $39.57M | 265,040 |
NVTNvent Electric Plc | $31.69M | 451,065 |
CNMCore & Main Inc | $21.10M | 475,195 |
VRNAVerona Pharma Plc | $19.74M | 686,045 |
RHCrh Plc | $15.07M | 162,500 |
TPGTpg Inc | $12.52M | 217,500 |
BKTIM & T Bk Corp | $10.01M | 56,200 |
TFCTruist Finl Corp | $9.99M | 233,500 |
HBANHuntington Bancshares Inc | $9.87M | 671,200 |
CFGCitizens Finl Group Inc | $9.80M | 238,600 |
ABCBAmeris Bancorp | $9.61M | 154,000 |
FCNCAFirst Ctzns Bancshares Inc N | $9.54M | 5,183 |
THCHArs Pharmaceuticals Inc | $7.79M | 536,900 |
TRPTc Energy Corp | $5.49M | 115,400 |
XPOXpo Inc | $5.00M | 46,500 |
PCVXVaxcyte Inc | $4.91M | 42,965 |
NAMSNewamsterdam Pharma Company | $4.77M | 287,535 |
RAREUltragenyx Pharmaceutical In | $4.75M | 85,445 |
ARMArm Holdings Plc | $3.09M | 21,610 |